Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sutro Biopharma Inc

0.9000
+0.175224.17%
Post-market: 0.90000.00000.00%19:00 EDT
Volume:3.11M
Turnover:2.55M
Market Cap:75.40M
PE:-0.30
High:0.9005
Open:0.7400
Low:0.7400
Close:0.7248
Loading ...

Sutro Biopharma, Boehringer announce application of Sutro’s technology

TIPRANKS
·
07 Jan

Great week for Sutro Biopharma, Inc. (NASDAQ:STRO) institutional investors after losing 42% over the previous year

Simply Wall St.
·
07 Jan

Sutro Biopharma, Inc.'s (NASDAQ:STRO) latest 24% decline adds to one-year losses, institutional investors may consider drastic measures

Simply Wall St.
·
20 Dec 2024

Sutro Biopharma Is Maintained at Equal-Weight by Wells Fargo

Dow Jones
·
12 Dec 2024

Truist Financial Reaffirms Their Buy Rating on Sutro Biopharma (STRO)

TIPRANKS
·
11 Dec 2024

Sutro Biopharma announces selected doses from REFRalphaME-O1

TIPRANKS
·
10 Dec 2024

Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results From Dose-Optimization Portion of RefrΑMe-O1 Trial in Platinum Resistant Ovarian Cancer

THOMSON REUTERS
·
10 Dec 2024

Sutro Biopharma Inc - Luvelta Positioned for Accelerated Approval Application in Mid-2027

THOMSON REUTERS
·
10 Dec 2024

Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer

GlobeNewswire
·
10 Dec 2024

Why Investors Shouldn't Be Surprised By Sutro Biopharma, Inc.'s (NASDAQ:STRO) 26% Share Price Plunge

Simply Wall St.
·
30 Nov 2024

Sutro Biopharma (STRO) Upgraded to Buy: Here's What You Should Know

Zacks
·
19 Nov 2024

Sutro Biopharma Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Dow Jones
·
18 Nov 2024

Sutro Biopharma (STRO) Receives a Buy from Truist Financial

TIPRANKS
·
15 Nov 2024

Sutro Biopharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.
·
15 Nov 2024

Sutro Biopharma Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
14 Nov 2024

Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Misses Revenue Estimates

Zacks
·
14 Nov 2024

Sutro Biopharma Q3 EPS $(0.59) Beats $(0.73) Estimate, Sales $8.52M Miss $15.25M Estimate

Benzinga
·
14 Nov 2024

BRIEF-Sutro Biopharma Q3 Revenue USD 8.52 Million

Reuters
·
14 Nov 2024

Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights

THOMSON REUTERS
·
14 Nov 2024

Sutro Biopharma Q3 Operating Expenses USD 76.439 Million

THOMSON REUTERS
·
14 Nov 2024